Background: Syncope is a common presenting complaint in the outpatient setting and requires a thoughtful and meticulous approach to history-taking skills. This is crucial in discerning cardiac versus non-cardiac etiologies, underscoring the pivotal role of healthcare professionals in the diagnostic process.

Case Report: This is a case of a 76-year-old male who presented to the primary care clinic following an episode of syncope with abrupt loss of consciousness. Given the presentation, there was a high suspicion of cardiac etiology, and further testing was pursued. An electrocardiogram (ECG) demonstrated normal sinus rhythm with a pre-existing first-degree atrioventricular (AV) block. The Holter monitor was without sustained arrhythmias. A dobutamine stress echocardiogram was negative for myocardial ischemia, though a resting transthoracic echocardiogram demonstrated findings consistent with cardiac amyloidosis. Further evaluation with cardiology confirmed the diagnosis of transthyretin (ATTR) cardiac amyloidosis. He was initiated on appropriate treatment and underwent a dual chamber implantable cardioverter defibrillator (ICD) given his presentation. The patient ultimately succumbed to his disease 5 years after his diagnosis.

Conclusion: If the cardiac etiology of syncope is suspected, further cardiac structural evaluation is necessary. Cardiac amyloidosis, although rare, is a cause of cardiogenic syncope that should not be overlooked. It should be considered in the differential diagnosis in the appropriate clinical setting, highlighting the need for a broad and comprehensive approach to diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1177/21501319241308025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11648006PMC

Publication Analysis

Top Keywords

cardiac amyloidosis
12
cardiac etiology
8
cardiac
7
amyloidosis
4
amyloidosis syncopal
4
syncopal enigma
4
enigma background
4
syncope
4
background syncope
4
syncope common
4

Similar Publications

Background: Concomitant cardiac amyloidosis (CA) and aortic stenosis (AS) may be mistaken for isolated AS, potentially impacting the treatment strategy and patient's prognosis. Therefore, it is crucial to distinguish between these conditions, as failure to promptly diagnose CA may lead to considerable complications. The aim of this study is to investigate the diagnostic value of strain predictors in patients with concomitant CA and AS compared to isolated AS.

View Article and Find Full Text PDF

Preprocedural Screening Tool to Guide Nonpulmonary Vein Trigger Testing in First-Time Atrial Fibrillation Ablation.

Circ Arrhythm Electrophysiol

December 2024

Section of Cardiac Electrophysiology, Division of Cardiovascular Medicine, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia.

Background: Patients undergoing first-time atrial fibrillation (AF) ablation can benefit from targeting non-pulmonary vein (PV) triggers. Preprocedural identification of high-risk individuals can guide planning of ablation strategy. This study aimed to create a preprocedural screening tool to identify patients at risk of non-PV triggers during first-time AF ablation.

View Article and Find Full Text PDF

Early Diagnosis and Treatment of Cardiac Amyloidosis by Screening Biopsy During Trigger Finger Release.

J Hand Surg Glob Online

November 2024

Division of Plastic and Reconstructive Surgery, Department of Surgery, University of California Davis, Sacramento, CA.

Patients undergoing trigger release surgery are known to be at increased risk of amyloidosis and heart failure, and therefore, amyloidosis screening during trigger release surgery may facilitate early diagnosis and treatment of cardiac amyloidosis. However, the reported prevalence of amyloid on biopsies taken during trigger release surgery has varied widely, and no biopsy-positive patients in prior studies have been diagnosed with occult cardiac amyloidosis or started on disease-modifying therapy. We review the existing literature on this topic and present a case of a patient with cardiac amyloidosis diagnosed from a biopsy taken during trigger release surgery and subsequently started on disease-modifying therapy.

View Article and Find Full Text PDF

Imaging of cardiac amyloidosis using dynamic F-FPYBF-2 positron emission tomography.

Ann Nucl Med

December 2024

Clinical Research Center, Shiga General Hospital, 5-4-30, Moriyama-Cho, Moriyama, Shiga, 524-8524, Japan.

Purpose: This study aimed to evaluate the diagnostic ability of 5-(5-(2-(2-(2-F-fluoroethoxy) ethoxy) ethoxy) benzofuran-2-yl)-N-methylpyridin-2-amine (F-FPYBF-2) dynamic PET for patients with cardiac amyloidosis (CA).

Methods: The subjects were patients diagnosed with proven amyloidosis (n = 16) including transthyretin cardiac amyloidosis (ATTR-CA) (n = 7) and light chain amyloidosis (AL amyloidosis) (n = 9), of which 4 and 5 with (AL-CA) and without (AL-nCA) cardiac involvement, and 4 control subjects suffering from some symptoms of cardiac failure without amyloidosis (CTL). Thirty minutes dynamic F-FPYBF-2 PET/CT was performed to evaluate the time activity curve and the retention index (mRI) as the ratio of the myocardial SUV at 15 to 5 min.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!